Vyome Holdings Highlights VT-1953 Market Potential Analysis

Vyome Holdings ( (HIND) ) has shared an update.

On January 27, 2026, Vyome Holdings released new data from an independent U.S. market assessment, commercial forecast and valuation analysis for VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. The study by Destum Partners highlights significant unmet need in this end-of-life oncology complication, identifies an absence of approved or late-stage competing therapies, and positions VT-1953 as a potential first-in-class topical treatment designed to address multiple core symptoms including malodor and pain. Destum’s base-case rNPV analysis values VT-1953 at $455 million in the United States as of Phase 2 completion, with modeled asset value rising to more than $1 billion in 2028 following anticipated Phase 3 completion, and implies a total U.S. addressable pharmacologic market for malignant fungating wound symptom treatment of about $2.2 billion in 2026, growing to $2.8 billion by 2040, underscoring the asset’s potential clinical and commercial importance and the strategic relevance of securing a partner with strong oncology supportive or wound-care capabilities.

The most recent analyst rating on (HIND) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.

Spark’s Take on HIND Stock

According to Spark, TipRanks’ AI Analyst, HIND is a Neutral.

The score is held down primarily by weak financial performance (shrinking revenue, deep losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events add some upside optionality, but valuation is difficult to justify with a negative P/E and no dividend support.

To see Spark’s full report on HIND stock, click here.

More about Vyome Holdings

Vyome Holdings, Inc. is a biopharmaceutical company focused on developing VT-1953, a topical, indication-specific therapy aimed at managing the symptoms of malignant fungating wounds, a rare and severe complication of advanced solid tumors. The company is targeting the oncology supportive care and wound-care markets, with a particular focus on palliative, hospice, and oncology settings where current treatment is fragmented, off-label, and lacks any FDA-approved options for this condition.

Average Trading Volume: 767,335

Technical Sentiment Signal: Strong Sell

Current Market Cap: $17.55M

For a thorough assessment of HIND stock, go to TipRanks’ Stock Analysis page.